

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women. (Visit www.avac.org/hvad for vaccine and broadly neutralizing antibody pipelines.)

| PRE-CLINICAL | | | PHASE I | | PHASE II | | PHASE III/IIIb/IV | | DELIVERY SYSTEM | ACTIVE DRUG |
|---|--|---|----------------------------|--|--|-------------|--------------------------|---------------------|------------------------------------|------------------------------------|
| TAF | CONRAD | MAVR Nigerian Institute for Medical Research | MAVR | ViiV/Pfizer | ELVG CONRAD | DS03 | Pop Council | F/TAF | Gilead Daily | 5P12 5P12-RANTES |
| CAB | CONRAD | CAB PATH/ Queens University Belfast | DPVR | University of Pittsburgh | TNFV | MK20 | University of Pittsburgh | LEN | Gilead 6-monthly | AMPR Amphora |
| CAB | CONRAD | DS03 Queen's University Belfast | 5P12 | Mintaka | TAF | GRFT | University of Pittsburgh | CAB | ViiV-GSK ² 2-monthly | BNAB Broadly neutralizing antibody |
| TNFV | Gilead | BNAB Rockefeller University | TAF | RTI | OB2H | Orion | | DPVR | Pop Council 1-monthly | CAB Cabotegravir/GSK 744 |
| F/TAF | Houston Methodist | CAB ViiV | | | | | | | | COP Copper |
| Multipurpose Prevention Technologies (MPTs) | | | | | | | | | | |
| CAB CONRAD/Eastern Virginia Medical School | DPVR University of North Carolina | F/TDF UMass and Planet Biotechnology/Oak Crest/MassBiologics | TAF CONRAD | ELVG | GRCG | Pop Council | F/TDF ETED LVGR | Viatis ³ | | CRGN Carrageenan |
| PRGT Magee-Women's Research Institute/University of Pittsburgh | ETGS ISL ETED | University of North Carolina | DPVR LVGR | Magee-Women's Research Institute/U. of Pittsburg | | | SPL7 | Starpharma Ltd. | | DPVR Dapivirine |
| F/TDF MAB | Oak Crest/University of North Carolina | CAB LVGR | CONRAD | TBD | | | | | | F/TAF Descovy |
| ETGS QGRF ETED | Pop Council/Oak Crest Institute of Science | QGRF ORAC | Pop Council | COP ZINC LAC | POP Council, QU Belfast, WC Medical College | | | | | DLGR Dolutegravir |
| QGRF ORAC | Pop Council/Evofem Biosciences | GRFT | Pop Council | ETGS EFDA | UW, Methodist Hospital Research Institute (HMRI) | | | | | DS03 DS003 (BMS793) |
| ISL | University of North Carolina | DPVR METD | Queen's University Belfast | COP | University of Washington (UW) | | | | | EFAV Efavirenz |
| PPCM | Yaso Therapeutics | DPVR COP ZINC | Queen's University Belfast | | | | | | | ELVG Elvitegravir |
| | | METD RPVR | Queen's University Belfast | | | | | | | EMCB Emtricitabine |

¹ This is a Bioequivalency trial with the monthly DVR.
² Dec. 2021 Approved by the FDA; Aug. 2022 Approved by the Australian regulatory agency.
³ The dual pill products is undergoing bioequivalency trials. The drug components are approved, but not in their combination. Therefore, it does not follow the traditional R&D pathway..
⁴ See SCHIELD Implant for more information.
⁵ ARV-based component to be determined.